✦ LIBER ✦

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes

✍ Scribed by Prebet, Thomas; Braun, Thorsten; Beyne-Rauzy, Odile; Dreyfus, Francois; Stammatoullas, Aspasia; Wattel, Eric; Ame, Shanti; Raffoux, Emmanuel; Delaunay, Jacques; Charbonnier, Aude; Adès, Lionel; Fenaux, Pierre; Vey, Norbert

Book ID: 122199348
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 443 KB
Volume: 38
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.07.023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pilot study on combination of azacitidin

Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast

✍ Joon Ho Moon; Soo Jung Lee; Yoo Jin Lee; Byung Woog Kang; Yee Soo Chae; Jong Gwa 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 192 KB

Idarubicin, cytarabine, and topotecan in

Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

✍ Seung Tae Lee; Joon Ho Jang; Hyung Chan Suh; Jee Sook Hahn; Yun Woong Ko; Yoo Ho 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

P-289 Effect of low-dose cytarabine and

P-289 Effect of low-dose cytarabine and aclarubicin in combination with decitabine on the outcome of patients with high-risk myelodysplastic syndromes

✍ Pian, S.; Duan, L.; Zhu, Y.; Hong, M.; Zhang, R.; Zhang, S.; Liu, P.; Lu, H.; Wu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 91 KB

A combination chemotherapy with low dose

A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage: A pilot study

✍ Shin-ichiro Kuriya; Kazunori Murai; Yasuro Miyairi; Taiju Utsugisawa; Yasushi Na 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 442 KB 👁 2 views

## BACKGROUND. Even now, no definitely effective therapy is inducted to high risk myelodysplastic syndromes (MDS) and their leukemic stage (MDS-AML) except bone marrow transplantation. ## METHODS. Ten patients with high risk MDS and 6 with MDS-AML were treated with daily low doses of cytarabine

Effective salvage therapy for high-risk

Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide

✍ Lee, Yun-Gyoo; Kwon, Ji-hyun; Kim, Inho; Yoon, Sung Soo; Lee, Jong-Seok; Park, S 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB

The combination of rituximab, bendamusti

The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia

✍ Visco, Carlo; Finotto, Silvia; Pomponi, Fabrizio; Sartori, Roberto; Laveder, Fra 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB